摘要
目的观察金匮肾气丸联用葡萄糖酸钙治疗原发性骨质疏松症骨量减少的临床疗效。方法选择2008年04月～2010年03月本院门诊及住院的获得完整随访资料的原发性骨质疏松症患者90例,随机分为A组(金匮肾气丸+葡萄糖酸钙组)30例,口服金匮肾气丸3g 3次/日;同时口服葡萄糖酸钙1g 3次/日;B组(葡萄糖酸钙组)30例,口服葡萄糖酸钙1g 3次/日;C组(阿法骨化醇组)30例,口服阿法骨化醇胶丸0.25U 2次/日。疗程6个月。治疗组与对照组在疼痛评分、骨密度变化、血钙、血清碱性磷酸酶检查结果方面进行比较。结果 A、B、C 3组患者疼痛评分较治疗前均明显降低,差异有显著统计学意义(P<0.01)。A组患者疼痛评分下降较B、C组明显,差异有统计学意义(P<0.05);A、B、C 3组患者治疗后骨密度均较前升高,差异有显著统计学意义(P<0.01)。A组较B、C组骨密度上升程度明显,组间比较有统计学差异(P<0.05)。A、B、C 3组患者治疗前后血清钙、磷、碱性磷酸酶检查结果比较,差异无统计学意义(P>0.05)。结论金匮肾气丸联用葡萄糖酸钙治疗原发性骨质疏松症临床疗效显著。
Objective To observe the clinical efficacy of combined use of Jinguishenqiwan and Calglucon on primary osteoporosis. Methods Ninety primary osteoporosis patients, diagnosed out- and in-clinic of our hospital from April 2008 to March 2010 with intact follow-up data, were randomly divided into following groups. Thirty patients in group A were treated with oral Jinguisbenqiwan 3g per time, 3 times per day, and Calglucon 1g per time, 3 times per day. Thirty patients in group B were treated with oral Calglucon 1g per time, 3 times per day. Thirty patients in group C were given oral α-calciferol 2u per time, 2 times per day. The treatment lasted for 6 months. The pain scales, bone mineral density （BMD） , serum calcium, and serum alkaline phosphatase were measure and compared between the treatment and control groups. Results The pain scales in A, B, and C groups decreased obviously after the treatment, with statistical significance （ P 〈 0.05 ）. The pain scale in patients of group A decreased more obviously than those in group B and C, with statistical significance （P 〈 0. 05）. BMD in patients of group A, B, and C increased after the treatment, compared to that before the treatment, with statistical significance （P 〈 0. 01 ）. The increase in group A was more obviously than that in group B and C, with statistical significance （ P 〈 0. 05 ）. The differences of serum calcium, phosphate, and alkaline phosphatase among the patients of group A, B, and C were not significant statistically before and after the treatment （P 〉 0. 05 ）. Conclusion The clinical efficacy of combined use of Jinguishenqiwan and Calglucon on primary osteoporosis is obvious.
出处
《中国骨质疏松杂志》
CAS
CSCD
2011年第10期912-914,911,共4页
Chinese Journal of Osteoporosis
基金
无锡市科技局科技(CSZ00855)
